Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Aptose Biosciences, Inc. - Common Shares (TSX:APS)

2.310 -0.030 (-1.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	15,933
Open	2.370
Bid (Size)	2.310 (65)
Ask (Size)	2.370 (11)
Prev. Close	2.340
Today's Range	2.310 - 2.370
52wk Range	0.1550 - 5.800
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

November 19, 2025

Aptose Biosciences minority shareholders to receive C$2.41 in cash per share in a “go private” transaction

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Reports Third Quarter 2025 Results

November 13, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Performance

YTD	+600.0%	+600.0%
1 Month	+29.1%	+29.1%
3 Month	+46.2%	+46.2%
6 Month	-2.1%	-2.1%
1 Year	+579.4%	+579.4%

More News

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

November 03, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

October 16, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML

September 22, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

August 22, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

August 18, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Reports Second Quarter 2025 Results

August 13, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

August 06, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

August 01, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

July 15, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Upgraded to Trade on OTCQB Market

July 01, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Announces Deferral of Interest Payment

June 30, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

June 20, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Provides Corporate Updates

June 17, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

June 12, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Announces Results from Annual and Special Meeting of Shareholders

May 27, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

May 20, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

May 14, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Reports First Quarter 2025 Results

May 08, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

May 05, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Announces Auditor Not Standing for Re-Appointment

April 23, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

April 23, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

April 01, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Reports Year End 2024 Results and Corporate Highlights

March 28, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Aptose Biosciences, Inc. - Common Shares publicly traded?

Yes, Aptose Biosciences, Inc. - Common Shares is publicly traded.

What exchange does Aptose Biosciences, Inc. - Common Shares trade on?

Aptose Biosciences, Inc. - Common Shares trades on the Toronto Stock Exchange

What is the ticker symbol for Aptose Biosciences, Inc. - Common Shares?

The ticker symbol for Aptose Biosciences, Inc. - Common Shares is APS on the Toronto Stock Exchange

What is the current price of Aptose Biosciences, Inc. - Common Shares?

The current price of Aptose Biosciences, Inc. - Common Shares is 2.310

When was Aptose Biosciences, Inc. - Common Shares last traded?

The last trade of Aptose Biosciences, Inc. - Common Shares was at 11/21/25 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.